An2 Therapeutics, INC. (ANTX) — 8-K Filings

8-K Filings (12)

• 8-K Filing — Apr 9, 2026
• AN2 Therapeutics Reports Unregistered Equity Sales — Jun 20, 2025 Risk: medium
  AN2 Therapeutics, Inc. filed an 8-K on June 20, 2025, reporting unregistered sales of equity securities that occurred on June 17, 2025. The filing also includes
• 8-K Filing — Jun 11, 2025
• AN2 Therapeutics Files 8-K on Shareholder Vote Matters — May 27, 2025 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders as of May 22, 2025. The filing details the com
• AN2 Therapeutics Files 8-K Report — May 1, 2025 Risk: low
  On May 1, 2025, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, with no specific material events or
• AN2 Therapeutics Files 8-K on Operations & Financials — Mar 25, 2025 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on March 25, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhib
• AN2 Therapeutics Appoints New Director, Discloses Officer Compensation — Nov 5, 2024 Risk: low
  AN2 Therapeutics, Inc. announced on November 4, 2024, a change in its board of directors. Specifically, Dr. Richard S. Gaynor has been appointed as a new dir
• AN2 Therapeutics Files 8-K: Material Agreement — Aug 19, 2024 Risk: medium
  AN2 Therapeutics, Inc. announced on August 15, 2024, that it entered into a Material Definitive Agreement. The filing also indicates modifications to the rights
• AN2 Therapeutics Announces Director Changes and Compensatory Arrangements — Aug 8, 2024 Risk: medium
  On August 7, 2024, AN2 Therapeutics, Inc. filed an 8-K report detailing several key events. The company announced the departure of Director Dr. Jonathan Leff an
• AN2 Therapeutics Files 8-K on Security Holder Votes & Financials — Jun 24, 2024 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on June 24, 2024, reporting on matters submitted to a vote of security holders and financial statements. The filing date for
• AN2 Therapeutics Files 8-K on Financials — Mar 28, 2024 Risk: low
  On March 28, 2024, AN2 Therapeutics, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as wel
• AN2 Therapeutics Files Routine 8-K for 'Other Events' — Feb 12, 2024 Risk: low
  AN2 Therapeutics, Inc. filed an 8-K on February 12, 2024, to report an "Other Event." This filing primarily serves to update the public record regarding the com

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX